BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36338740)

  • 1. Gonadotropin-releasing hormone agonist protects ovarian function in young patients with ovarian malignancy undergoing platinum-based chemotherapy: A prospective study.
    Xie Y; Duan H; Wang D; Li H; Jia J; Zhang J; Li L
    Front Oncol; 2022; 12():986208. PubMed ID: 36338740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility and efficacy of gonadotropin-releasing hormone agonists for the prevention of chemotherapy-induced ovarian insufficiency in patients with malignant ovarian germ cell tumours (KGOG 3048R).
    Choi MC; Chung YS; Lee JW; Kwon BS; Park BK; Kim SI; Shim SH; Lee KB; Seong SJ; Lee SJ; Lee SH; Yoo HJ; Song T; Kim MK; Baek MH; Kang S; Kim YM
    Eur J Cancer; 2020 Jul; 133():56-65. PubMed ID: 32442924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of ovarian function recovery in young breast cancer patients after protection with gonadotropin-releasing hormone agonist during chemotherapy.
    Lee DY; Park YH; Lee JE; Choi D
    Breast Cancer Res Treat; 2018 Oct; 171(3):649-656. PubMed ID: 29943121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
    Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
    Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-Müllerian hormone as a new marker of the ovarian reserve function preservation by goserelin during (neo)adjuvant chemotherapy for young breast cancer patients].
    Wang SY; Wang S
    Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Jun; 51(3):536-541. PubMed ID: 31209428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
    Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
    JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
    Chen H; Xiao L; Li J; Cui L; Huang W
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gonadotropin-Releasing Hormone Agonist Cotreatment During Chemotherapy May Increase Pregnancy Rate in Survivors.
    Blumenfeld Z; Zur H; Dann EJ
    Oncologist; 2015 Nov; 20(11):1283-9. PubMed ID: 26463871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the benefit of gonadotropin-releasing hormone agonist treatment in premenopausal women undergoing hematopoietic cell transplantation.
    Han R; Song Z; Li H; Wang C; Zhang L; Yang X
    Sci Rep; 2023 Sep; 13(1):14497. PubMed ID: 37666835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.
    Li X; Kang X; Deng Q; Cai J; Wang Z
    Reprod Biol Endocrinol; 2013 Mar; 11():16. PubMed ID: 23452939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer.
    Zhong Y; Lin Y; Cheng X; Huang X; Zhou Y; Mao F; Wang Y; Guan J; Shen S; Xu Y; Peng L; Li Y; Cao X; Sun Q
    J Cancer; 2019; 10(18):4278-4285. PubMed ID: 31413747
    [No Abstract]   [Full Text] [Related]  

  • 14. Gonadotropin-Releasing Hormone Agonists for Ovarian Function Preservation in Premenopausal Women Undergoing Chemotherapy for Early-Stage Breast Cancer: A Systematic Review and Meta-analysis.
    Munhoz RR; Pereira AA; Sasse AD; Hoff PM; Traina TA; Hudis CA; Marques RJ
    JAMA Oncol; 2016 Jan; 2(1):65-73. PubMed ID: 26426573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Gaillard I; Zachee P; Casasnovas RO; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2013 Mar; 31(7):903-9. PubMed ID: 23129737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer.
    Shin JJ; Choi YM; Jun JK; Lee KH; Kim TY; Han W; Im SA
    J Breast Cancer; 2020 Jun; 23(3):268-278. PubMed ID: 32595989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian reserve in premenopausal women with breast cancer.
    Zong X; Yu Y; Chen W; Zong W; Yang H; Chen X
    Breast; 2022 Aug; 64():143-150. PubMed ID: 35691250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro.
    Bildik G; Akin N; Senbabaoglu F; Sahin GN; Karahuseyinoglu S; Ince U; Taskiran C; Selek U; Yakin K; Guzel Y; Ayhan C; Alper E; Cetiner M; Balaban B; Mandel NM; Esen T; Iwase A; Urman B; Oktem O
    Hum Reprod; 2015 Dec; 30(12):2912-25. PubMed ID: 26466909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis.
    Clowse ME; Behera MA; Anders CK; Copland S; Coffman CJ; Leppert PC; Bastian LA
    J Womens Health (Larchmt); 2009 Mar; 18(3):311-9. PubMed ID: 19281314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No Evidence for the Benefit of Gonadotropin-Releasing Hormone Agonist in Preserving Ovarian Function and Fertility in Lymphoma Survivors Treated With Chemotherapy: Final Long-Term Report of a Prospective Randomized Trial.
    Demeestere I; Brice P; Peccatori FA; Kentos A; Dupuis J; Zachee P; Casasnovas O; Van Den Neste E; Dechene J; De Maertelaer V; Bron D; Englert Y
    J Clin Oncol; 2016 Aug; 34(22):2568-74. PubMed ID: 27217453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.